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Abstract
Background: Cervical cancer is one of the most common female cancers and is caused by human papillomavirus
(HPV). Viral infection leads to cell cycle deregulation by inactivating p53 and retinoblastoma protein by viral
oncoproteins E6 and E7, respectively. Then, nuclear proteins such as DNA topoisomerase type IIa (TOP2A) and
Ki-67 show increased expression because of increased cell division. These molecules are used as biomarkers
for immunohistochemistry analysis of cervical tissue.
Methods: In this cross-sectional study, we recruited 110 women receiving regular gynecological surveillance
at public health centers in Olinda – PE, Brazil. Cervicovaginal cells were collected to determine the presence
of cytological abnormalities and HPV infection. Pap smear slides were used to evaluate the expression of
TOP2A and Ki-67 using immunocytochemistry techniques.
Results: Of the 110 women, 75.4 % showed HPV-DNA+ infection (83/110) and 29.1 % showed cellular abnormalities
(32/110). Two atypical cells of undetermined significance, one low-grade squamous intraepithelial lesion, and
one high-grade squamous intraepithelial lesion samples showed no HPV-DNA. TOP2A was positive in 71.9 % of
samples, while Ki-67 was positive in 81.2 %. Immunocytochemistry results were positive in 4 of 5 atypical cells of
undetermined significance samples. In HPV-DNA+ samples with cytological abnormalities, immunocytochemistry
results were positive 96.4 % of samples (p < 0.0001; odds ratio = 28.0). Among the samples infected with HR-HPV,
TOP2A+ was effective in 71 % samples, while and Ki-67+ was 77.4 %. Ki-67 and TOP2A were positive for all
samples infected with HPV6, HPV11, and HPV18. Ki-67 was also positive for all HPV16 samples, except for one
negative sample in cytopathology analysis.
Conclusions: TOP2A and Ki-67 antibodies may be used in combination for cervical cancer screening in
immunocytochemistry assays.
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Background
Worldwide, cervical cancer is the third most common
female cancer. In 2012, 527,624 cases were reported.
This number is expected to increase by 6.23 % in 2015,
reaching to 560,505 cases [1, 2]. Cervical cancer develop-
ment is associated with persistent human papillomavirus
(HPV) infection. Among more than 100 HPV genotypes,
HPV16 and HPV18 alone are responsible for 73 % of
cervical cancer cases [3, 4].
The viral oncoproteins E6, E7, and E5 deregulate the
cell cycle and structure [5, 6], leading to cellular pro-
liferation and morphological abnormalities. Therefore,
molecules related to cell cycle regulation [p53, p21,
Bcl-2-associated X protein, p27, retinoblastoma pro-
tein, p16 INK4a, minichromosome maintenance protein
2 (MCM2), topoisomerases type IIa (TOP2A), cyclin D1,
cyclin A, and cyclin E] and cell proliferation (proliferating
cell nuclear antigen, Ki-67, and c-myc) are used as bio-
markers for cervical cancer diagnosis [6].
TOP2A is responsible for enzymatic uncoupling dur-
ing the replication of DNA strands, playing a significant
role in S-phase regulation. TOP2A is overexpressed
during the progression from cervical intraepithelial
neoplasia 2 (CIN2)-CIN3 to cervical cancer, and thus it
is considered to be a late marker of cervical carcinogen-
esis [7, 8]. The combination of TOP2A and MCM2 in
the commercial assay ProExC™ is used for immunohis-
tochemistry analysis in cervical cancer samples.
Ki-67 is a nuclear and nucleolar protein expressed
during all phases of the cell cycle, except for the G0
phase [8]. Ki-67 expression is typically confined to the
basal and parabasal layers of the normal cervical squa-
mous epithelium. However, in dysplasia and carcinoma,
expression extends above one-third of the epithelium.
Therefore, Ki-67 is a reliable marker for cell cycle
deregulation caused by HPV infection and is related
to the risk of progression from precursor lesions to
carcinoma [9, 10].
The aim of this study was to determine the feasibility
of using immunocytochemistry for TOP2A and Ki-67 on
cytopathology slides to improve the accuracy of cervical
cancer screening.
Methods
Study design and case selection
This cross-sectional study included women under sur-
veillance at public health centers in Brazil. Samples
consisted of 110 patients aged 13–71 years from 3 fa-
milial health units located in Olinda-PE. During regular
gynecological inspection, all patients underwent Pap
testing and HPV-DNA investigation. Exclusion criteria
were: HIV infection, pregnancy and post-partum, his-
tory of transplant, history of partial or complete uterus
removal, and immunocompromised patients. This study
was approved by institutional ethical committee Health
Sciences Center Federal University of Pernambuco, Brazil
(Code No.275/08) and conducted according to the guide-
lines of the Declaration of Helsinki (1964).
Cervical samples
Cervical samples were harvested from the ectocervix
and endocervix using a spatula and cytobrush (Kolplast,
São Paulo, Brazil), respectively. Collected cells were trans-
ferred to a glass slide, identified, and then fixed in absolute
ethanol (Vetec, Rio de Janeiro, Brazil; Sigma-Aldrich,
St. Louis, MO, USA) until sample preparation for cyto-
pathology and immunocytochemistry analysis at Path-
ology Sector – LIKA/UFPE. The residual cells in the
cytobrush were stored in phosphate-buffered saline (PBS),
pH 7.0 (Life Technologies, USA) at −20 °C before HPV
identification and genotyping at Molecular Prospection
Sector – LIKA/UFPE. For analysis, patients were divided
into four groups according to Pap test and HPV-DNA
identification: (1) women with cervical abnormalities and
HPV-DNA positive; (2) women with cervical abnormal-
ities and HPV-negative; (3) women with normal cytology
and HPV-DNA positive; and (4) women with normal
cytology and HPV-negative (control group).
Cytological analysis
All samples underwent Papanicolaou staining [11] and were
categorized according to the 2001 Bethesda System nomen-
clature for cervical cytology. Four categories were used, as
follows: negative for intraepithelial lesion or malignancy
(NILM), atypical squamous cells of undetermined signifi-
cance (ASC-US), low-grade squamous intraepithelial lesion
(LSIL), and high-grade squamous intraepithelial lesion
(HSIL) [12]. Two independent cytopathologists (A.L.P. and
N.T.P.F) assessed all slides in a double-blinded manner and
contradictory findings were resolved through discussion.
HPV-DNA identification
Total DNA extraction was performed using the Wizard
Genomic DNA Purification Kit (Promega, Madison, WI,
USA) following the manufacturer’s instructions. Eluted
DNA was stored at −20 °C until HPV-DNA identification.
Conventional PCR was performed in a Verity® Thermal
Cycler (Thermo Fischer Scientific, Waltham, MA, USA)
using two consensus primers: GP5+/GP6+ [13] or MY09/
MY11 [14] purchased from Integrated DNA Technologies
(Coralville, IA, USA). β-Actin was used as a housekeeping
gene (Fw: 5′-AGC GGG AAA TCG TGC GTG-3′ and
Rv: 5′-GGT GAT GAC CTG GCC GTC-3′) to ensure the
quality of DNA extracted. The reaction mix was prepared
with 1 μL DNA (80–100 ng), 1 μM of each primer, and
12.5 μL Go Taq Green MasterMix (Promega) in a final
volume of 25 μL. The PCR was performed as follows:
(i) initial denaturation at 94 °C for 2 min; (ii) 34 cycles
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of denaturation at 95 °C for 1 min, (iii) annealing at
45 °C (for GP5+/6+) or 55 °C (for MY09/11) or 60 °C (for
β-actin) for 1 min; and (iv) extension at 72 °C for 1 min. A
final extension was performed at 72 °C for 5 min. A plas-
mid containing the HPV16 complete genome was used as
a positive control. Ultrapure water was used as a negative
control. Amplicons were observed on a 1 % agarose gel
stained with ethidium bromide (0.5 mg/mL final concen-
tration). All samples were analyzed twice for each primer
pair in independent experiments. HPV-positive results
were assumed for samples with at least two positive
results in HPV amplification.
HPV-DNA genotyping
Cervical samples assumed as positive for HPV-DNA
or presenting cytological abnormalities were evaluated
using the PapilloCheck® Test Kit (Greiner Bio-One
GmbH, Frickenhausen, Germany), according to the manu-
facturer’s instructions. This chip-based assay identifies 18
HPV genotypes classified as high-risk (HR) or probable
HR-HPV (16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59,
66, 68, 70, 73, 82) and 6 low-risk (LR) HPV (HPV6, 11, 40,
42, 43, 44/55). The test cannot distinguish between
HPV-55 and HPV-44 because of a cross-reaction, and
the manufacturer instructions do not differentiate HR-
HPV from probable HR-HPV. Slide scanning was per-
formed using a Greiner Bio-One CheckScanner™. Data
analysis was performed using CheckReport™ Software.
Since PapilloCheck® requires highly pure and concen-
trated DNA (400–800 ng input), all samples that did
not fulfill the criteria were excluded from the study.
Immunocytochemistry procedures
Immunocytochemistry (ICC) was performed on the Pap
smear slides by removing coverslips in xylene and rehy-
drating the samples in decreasing concentration of
ethyl alcohol [15]. To test two antibodies (anti-TOP2A
and anti-Ki-67) on the same slide, a hydrophobic bar-
rier was introduced using the Dako Pen S2002 (Dako,
Carpinteria, CA, USA) to prevent mixing of the anti-
body solutions. The design of the separation line oc-
curred after careful observation of the slide to ensure
the presence of cells with morphological abnormalities
on both sides of the barrier. Counterstain using Harry’s
hematoxylin was performed before slide assembly. Im-
munostaining was performed with antibodies against
Ki-67 (Clone MIB-1, Dako) and TOP2A (Clone Ki-S1,
Dako) at 1:50 and 1:100 dilutions, respectively. Both
antibody solutions were prepared in PBS, pH 7.2, con-
taining 1 % bovine serum albumin (Thermo Fischer
Scientific). Starr Trek Universal HRP Detection System
(BIOCARE MEDICAL, Concord, CA, USA) was used
according to manufacturer’s instructions. Slides were
evaluated using an Olympus microscope (Tokyo, Japan)
at 400× magnification. Two slides well-known to be
immunoreactive for Ki-67 and TOP2A were used as
positive controls in each batch: (1) a slide containing a
tissue section from cervical cancer biopsy and (2) a
slide containing cytological samples from invasive squa-
mous cell carcinoma. PBS, pH 7.2, was used as a negative
control. Slides were assumed to be positive for TOP2A or
Ki-67 when at least one cell showed a dark brown nucleus
(Fig. 1a–d). Immunocytochemistry results were catego-
rized into four groups: Ki-67+; TOP2A+; Ki-67+/TOP2A+
(positive for both markers); and Ki-67+ and/or TOP2A+
(positive for at least one marker on the same slide), desig-
nated as ICC+. Two independent cytopathologists (A.L.P.
and N.T.P.F) assessed all slides in a double-blinded man-
ner; contradictory findings resolved through discussion.
Statistical analysis
Statistical analysis was performed using Prism software
v6.0 (GraphPad, Inc., La Jolla, CA, USA). The associ-
ation between groups according to cytopathology, im-
munocytochemistry, and PCR results were performed by
Chi-square test or Fischer exact test with 95 % confi-
dence intervals (95 % CI) and odds ratio (OR). Statistics
were significant when p < 0.05. The concordance be-
tween Ki-67 and TOP2A results were analyzed using




Among the 110 patients, the median age was 30 years,
77.8 % declared household incomes up to two minimum
wages, and 95.4 % had no more than a high school
education level (Table 1). Most women were married
(53.7 %), reported the first sexual intercourse after
16 years old (59.4 %), and had fewer than three sex-
ual partners (51.4 %). Multiparous women represented
56.4 % of the patients, varying from 2 to 11 children
each. Abortion was reported by 33.6 % of the patients,
including two nulliparous women. Only 1.8 % of the
patients reported the use of oral contraceptive methods. A
total of 28.2 % of women reported tubal ligation, a factor
for HPV infection in this group (p = 0.0013; OR = 4.779).
The youngest patient to report tubal ligation was 26 years,
she used no other contraceptive method, had her first
pregnancy at 19 years, and had 5 children. Smoking habits
and alcohol consumption were reported by 34.5 and
54.5 % of patients, respectively.
Of the 110 women, 75.4 % showed HPV-DNA+ infec-
tion (83/110) and 29.1 % showed cellular abnormalities
(32/110). Twenty-eight samples were positive for both
tests, cytopathology, and HPV-DNA (87.5 %). Two
ASC-US, one LSIL, and one HSIL sample showed no
HPV-DNA (Table 2).
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Immunocytochemistry analysis
In samples with cytological abnormalities, TOP2A was
positive in 71.9 % of the samples, while Ki-67 was posi-
tive in 81.2 % of the samples. Comparison of the two
markers showed that TOP2A was more efficient for
HSIL, as expected for a prognosis cancer biomarker.
Ki-67 was more effective for detecting ASC-US and
LSIL, as it indicates cellular proliferation. The positive
rate of TOP2A and Ki-67 increases when cervical lesion
severity increases. The concordance between TOP2A
and Ki-67 results was 78.2 % (κ = 0.56; moderate agree-
ment; p < 0.0001).
When evaluated as a single test, the positive rate for
ICC+ was 93.7 % in the group with cervical abnormalities.
The ICC+ test showed OR = 22.74, which was higher than
those of Ki-67+ (OR = 11.76) and TOP2A (OR = 4.56).
The concordance between the cytopathology and ICC test
was 70 % (κ = 0.43; p < 0.0001).
The samples categorized as NILM corresponded to
70.9 % (78/110). Among these samples, 70.5 % (55/78)
were HPV-DNA+. TOP2A+ and Ki-67+ were observed in
36 and 27 % of samples, respectively. ICC+ results were
observed in 39.7 % of samples (31/78). Twenty-seven
samples (49.1 %) were HPV-DNA+ and ICC-negative.
Only four samples (7.3 %) were HPV-negative and ICC+.
Table 3 shows TOP2A and Ki-67 staining according to
HPV infection. In HPV-DNA+ samples with cytological
abnormalities, the ICC+ result was 96.4 % (p < 0.0001;
OR = 28.0). In the HPV-negative group, the overall ICC+
rate was 33.3 %, identifying 3 of 4 HPV-negative samples.
The overall ICC+ result in HPV-DNA+ samples was 64 %,
with similar positivity between both markers.
Samples infected with HPV-DNA or showing cyto-
logical abnormalities were selected for genotyping. A
total of 83 samples were considered for genotyping, but
seven samples were excluded because of low quality,
including three ASC-US and one LSIL. Therefore, 76
samples were evaluated for HPV genotypes, including 28
samples with cytological abnormalities and 74 HPV-
DNA+ samples.
HPV genotypes were identified in 34 samples (43.6 %),
of which 31 (91.2 %) were infected with the HR-HPV
genotypes. Nine patients were infected with HPV16 and
three patients were infected with HPV18 (Table 4). Thir-
teen samples showed multiple infections including up to
3 HPV genotypes. One patient was infected with HPV16
and HPV18. Only one sample (LSIL) was infected exclu-
sively with LR-HPV genotypes (HPV6 and HPV11).
Among the samples infected with HR-HPV, we found
71 % TOP2A+ samples and 77.4 % Ki-67+ samples. Ki-67
Fig. 1 a Papanicolaou staining of cervical cells showing syncytial arrangement with dyskaryosis characterizing HSIL (magnification: 400×).
b TOP2A-positive immunocytochemistry of cervical cells at similar syncytial arrangement (magnification: 400×). c Papanicolaou staining of
cervical cells showing syncytial arrangement with dyskaryosis, (magnification: 400×). d Ki-67-positive immunocytochemistry of cervical cells
with similar syncytial arrangement (400×)
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and TOP2A were positive for all samples infected with
HPV6, HPV11, and HPV18. Ki-67 was also positive for
all HPV16 samples, except for one negative sample in
cytopathology analysis. Twenty-seven samples (37.2 %)
showed negative results for the Papillocheck test, includ-
ing one HSIL (ICC+), two LSIL samples, and one ASC-US
(HPV-DNA+ and ICC+). Genotyping tests failed in 15
samples, including two LSIL (ICC+). Of the 37 NILM
samples evaluated, 13 samples were infected with HR-
HPV and one sample was infected with LR-HPV.
Discussion
Our findings showed a high positive rate for the ICC+
test in samples with cytological abnormalities. TOP2A
was more effective for HSIL samples, while Ki-67 was
more effective for ASC-US and LSIL. A combination of
markers is necessary for cervical cancer screening systems
when the concordance between markers shows only mod-
erate agreement. TOP2A and Ki-67 were also useful for
identifying samples infected with HR-HPV, an important
result the potential of these markers for commercial
application.
HPV-DNA tests exhibit high sensitivity but low speci-
ficity and generally cannot distinguish clinically relevant
lesions from transient infections [16]. Thus, comple-
mentary biomarkers are needed to allow for such dis-
crimination [17]. ICC may improve the management of
cervical intraepithelial lesions following identification
of protein expression deregulation [18, 19]. Careful in-
terpretation of immunostaining results and morpho-
logical characteristics in conventional Pap smears can
be a very useful as laboratory approach. This approach
is also simple, reliable, and easily applicable in diagnos-
tic routines [6, 19].
Application of the Ki-67 marker has been investigated
in cervical cytology using classic Pap smears as a diag-
nostic adjunct for reducing the need for tissue biopsies
[18, 20–22]. Ki-67 immunocytochemistry shows good
accuracy for HSIL diagnosis and is used as an adjunct to
cytology [6, 23]. In the present study, Ki-67 was positive
in 81.2 % samples with cellular abnormalities, which is
comparable to the results of previous studies [19, 24].
Since Ki-67 is highly expressed epithelial cells during
proliferation, its positive staining can indicate an active
Table 1 Socio-demographic profile and clinical status of
110 patients enrolled in the study
HPV infection
Characteristics N N (%) p value
Total samples 110 83 75.4 0.3907
Age, years
< 16 7 6 85.7
16–30 49 34 69.4
> 30 54 43 79.6
Household income, minimum wage (R$)a 0.5369
< 2 84 65 77.4
2–5 25 17 68.0
> 5 1 1 100.0
Educational level 0.4321
High school or less 105 79 75.2
Incomplete college 3 3 100.0
College graduate 2 1 50.0
Matrimonial statusb 0.4050
Single 38 27 71.0
Married 58 46 79.3
Divorced 8 5 62.5
Widow 4 4 100.0
Age of first sexual intercourse, yearsc 0.2414
< 16 43 36 83.7
≥ 16 63 46 73.0
Sexual partnersd 0.3956
< 3 54 39 72.2
3–7 46 34 73.9
> 7 5 5 100.0
Parity 0.6964
Nulliparous 27 19 70.4
Primiparous 21 17 80.9
Multiparous (2–11) 62 47 75.8
Abortione 0.6082
Yes (1–5) 37 27 72.9
No 48 38 79.2
Oral contraceptive 1.00
Yes 2 2 100.0
No 108 81 75
Tubal ligation 0.0013
Yes 31 24 77.4
No 79 33 41.8
Smoking habit 0.6439
Yes 38 30 78.9
No 72 53 73.6
Table 1 Socio-demographic profile and clinical status of
110 patients enrolled in the study (Continued)
Alcohol consumption 0.0754
Yes 60 41 68.3
No 50 42 84.0
aMinimum wage = R$ 622.00; b2 patients did not answer the question;
c4 patients did not answer; d5 patients did not answer; eexcluding 25
patients that never were pregnant
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HPV infection [8, 25]. Studies of cellular biomarkers in
this field have described Ki-67 as a marker in cervical
ASC-US. Ki-67 tests may help to reduce the rate of ASC-
US, leading to differentiation of dysplasia from mimics
such as atypical metaplasia or atrophy in diagnostically
problematic cases [9, 26], although it is relatively nonspe-
cific for detecting cervical squamous dysplasia [23, 27].
TOP2A and Ki-67 were previously tested together
for immunohistochemistry in carcinoma and high-grade
cervical neoplasia (CIN2/3), revealing no relationship be-
tween stained nuclei counting and survival [28]. However,
another report showed that only TOP2A matched to all
HSIL samples, with better results than for Ki-67 [27, 29],
which agree with our ICC results. Studies also observed
Ki-67 and TOP2A in the vulvar epithelium, showing good
correlation for characterizing benign, intraepithelial, and
invasive neoplastic epithelial changes [30].
In our study, using both markers enabled identification
of cellular abnormalities in four of five ASC-US samples,
corroborating the results of previous studies focused on
atypical squamous cell cytology [5, 8, 27, 31]. We also
identified structural modifications in samples with cyto-
logical abnormalities without HPV-DNA identification.
This observation is in agreement with studies using
SurePath preparation, in which ICC with p16 and Ki-67
could identify high protein expression even in HPV-
negative ASC-US [10, 32] and ASC-H samples [5, 9].
HPV-DNA is normally positive in transient infections,
accounting for the majority of infected cases. However,
TOP2A staining as a maker of cell-cycle deregulation
and Ki-67 for uncontrolled proliferation are expected to
be positive only in dysplastic cells undergoing HPV-
mediated transformation. A negative result for ICC in
HPV+ samples indicates a low risk of cervical lesion de-
velopment in these patients, although HPV is present.
The association of p16/Ki-67 staining increased sensi-
tivity and specificity for identifying women at high-risk
for developing high-grade precancerous disease in a group
of HPV-positive patients with negative liquid-based Pap
cytology [6, 33]. Singh et al. (2012) also applied dual stain-
ing for p16INK4a/Ki-67 ICC and showed increased speci-
ficity and remarkable sensitivity for diagnosing CIN2/3 or
glandular lesions compared with PCR-based testing for
HR-HPV [34]. Finally, CINtec® PLUS, a commercial assay
for p16/Ki-67 determination, was strongly related to the
presence of CIN2+ lesions and was associated with
Table 2 Immunocytochemistry profile of TOP2A and Ki-67 antibodies related to cytopathology classification of cervical smears
Cytopathology N HPV+ (%) Immunocytochemistry
TOP2A+ (%) Ki-67+ (%) TOP2A+/Ki-67+ (%) ICC+ (%)
Positive 32*,**,***,**** 28 (87.5) 23* (71.9) 26** (81.2) 19*** (59.4) 30**** (93.7)
ASC-US 5 3 (60) 2 (40) 3 (60) 1 (20) 4 (80)
LSIL 19 18 (94.7) 13 (68) 16 (84) 11 (57.9) 18 (94.7)
HSIL 8 7 (87.5) 8 (100) 7 (87.5) 7 (87.5) 8 (100)
NILM 78 55 (70.5) 28 (36) 21 (27) 18 (23) 31 (39.7)
Total 110 83 51 47 37 61
*p < 0.0007 (OR = 4.563; 95 % CI: 1.857–11.21); **p < 0.0001 (OR = 11.76; 95 % CI: 4.245–32.59); ***p < 0.0007 (OR = 4.872; 95 % CI: 2.019–11.75); ****p < 0.0001
(OR = 22.74; 95 % CI 5.065–102.1)
Table 3 Immunocytochemistry analysis related to HPV-DNA in 110 cervical samples
Human
papillomavirus
N Ki-67+ TOP2A+ Ki-67+/TOP2A+ ICC+ (%)
N (%) p OR
(95 % IC)
N (%) p OR
(95 % IC)
N (%) p OR
(95 % IC)
N (%) p OR
(95 % IC)
HPV+ 83 45 (54.2) 0.0003 6.809
(2.16–21.43)
45 (54.2) 0.0142 3.383
(1.29–8.86)
36 (43.4) 0.0004 9.574
(2.12–43.11)




28 26 (92.8) 0.0001 24.63
(5.26–115.2)
20 (71.4) 0.0357 3.00
(1.12–7.96)
19 (67.8) 0.0021 4.791
(1.77–12.55)




55 19 (34.4) 25 (45.4) 17 (30.9) 27 (49.1)
HPV− 27 4 (14.8) 7 (25.9) 2 (7.4) 9 (33.3)
With cytological
abnormalities
4 0 (−) 0.4286 – 3 (75) 1.00 – 0 (−) 1.00 – 3 (75) 1.00 –
W/o cytological
abnormalities
23 2 (8.7) 3 (13.0) 1 (4.3) 4 (17.4)
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HR-HPV infection and an increasing grade of cervical
lesions [7, 17]. In our study, TOP2A+ and Ki-67+ showed
higher positive rates in samples infected with HR-HPV
compared to in biopsied paraffin blocks analyzed for
HPV16, 18, and 31 [35].
This is the first study investigating a combination of
TOP2A and Ki-67 as markers for ICC in HR-HPV infec-
tion. The present study has some limitations, including
the relatively small number of selected cases and the
use of material collected during routine gynecological
inspection of women under surveillance at public health
centers in Brazil.
Conclusions
TOP2A and Ki-67 may be a useful antibody combination
for cervical cancer screening in health services currently
using only conventional cytology. Further analyses are
required before considering these markers for clinical
follow-up in immunohistochemistry. Their performance
must also be compared with those of commercial assays.
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